+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating CYB003, a deuterated psilocin analog, as an additional treatment for adults with Major Depressive Disorder MDD. This Phase III study aims to assess the effectiveness, safety, and tolerability of two different doses of CYB003 compared to a placebo in people who continue their current antidepressant medication. The study is randomized, double-blind, and involves multiple centers. Participants are assigned to one of three groups two experimental arms receiving either 8 mg or 16 mg of CYB003 during two medicine sessions spaced about three weeks apart, or a placebo arm receiving placebo sessions on the same schedule. Throughout the trial, all participants maintain their current antidepressants and receive psychological support. Non-responders to placebo may join a later extension trial to receive CYB003. During the trial, participants undergo evaluations using several scales that assess depression severity, anxiety, global clinical impression, and quality of life at multiple time points from screening through up to 84 days or end of trial. Psychological support sessions and dosing visits are conducted, and safety is monitored. The total study participation lasts approximately three months, with detailed assessments scheduled at baseline and various days post-treatment.

Age: 18Years - 85YearsAll GendersPhase 3
79 locations
O

Actively Recruiting

This observational study focuses on patients with ATTR amyloidosis, aiming to gather real-world data on their disease journeys before and after diagnosis. It seeks to describe patient characteristics, treatment patterns, and outcomes, including clinical, economic, and quality of life measures. The study also aims to better understand how ATTR amyloidosis presents and affects daily living. The study does not involve any interventions, as it is a retrospective analysis of existing data from multiple countries. It includes patients with various types of ATTR amyloidosis, such as cardiomyopathy, neuropathy, wild type, hereditary, and mixed phenotypes. Data collected cover the period from before diagnosis up to the end of follow-up, which can last up to 12 years. Participants medical records will be reviewed to assess healthcare resource use, clinical measurements like neuropathy impairment scores, and humanistic outcomes such as quality of life and activities of daily living. The study will evaluate hospitalizations, outpatient visits, emergency visits, transplant events, and mortality over time. This long-term data collection helps characterize disease impact and resource use for patients with ATTR amyloidosis.

All AgesAll Genders
29 locations
E

Actively Recruiting

Researchers are evaluating COMP360, a lab-made version of the naturally occurring compound psilocybin, to see if it can reduce symptoms of post-traumatic stress disorder PTSD. This study is a phase 2b3 clinical trial involving participants diagnosed with PTSD at least six months prior. The trial is randomized, double-blind, and includes an open-label extension to investigate the safety, tolerability, and effectiveness of different doses. Participants receive COMP360 psilocybin at varying doses of 1 mg, 10 mg, or 25 mg, administered alongside monitoring and support from a trained study team. The study compares the effects of these doses using a parallel design, with the primary focus on how symptoms change by week 8 after treatment. The intervention is combined with support throughout the study to observe participant responses. During the trial, participants will undergo assessments to measure PTSD symptom severity using the CAPS-5 scale from baseline through week 8. The study includes regular monitoring and evaluation of safety and tolerability. Participation involves multiple visits over the study period, with close observation by the research team to track symptom changes and any side effects. The entire study is expected to complete by September 2029.

Age: 18Years +All GendersPhase 2Phase 3
10 locations